Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 3/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | UBE2M | P61081 | 9/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670182 | 0.85 | CETP (0.36) | RXRARXRGPTGESCETPUBE2M | |
| SCHEMBL1897361 | 0.81 | CETP (0.33) | RXRARXRGPTGESCETPTACR1 | |
| SCHEMBL1898087 | 0.79 | CETP (0.47) | CETP | |
| SCHEMBL1898564 | 0.79 | TACR1 (0.40) | RXRARXRGUBE2MDCUN1D1TACR1 | |
| SCHEMBL5150827 | 0.77 | UBE2M (0.34) | CETPUBE2MDCUN1D1TACR1 | |
| SCHEMBL5148332 | 0.76 | SERPINE1 (0.37) | UBE2MDCUN1D1TACR1CCR2 | |
| SCHEMBL5148327 | 0.75 | SERPINE1 (0.36) | UBE2MDCUN1D1TACR1CCR2 | |
| SCHEMBL5147180 | 0.74 | SERPINE1 (0.37) | UBE2MDCUN1D1TACR1CCR2 | |
| SCHEMBL5148370 | 0.73 | PSEN1 (0.36) | UBE2MDCUN1D1TACR1CCR2 | |
| SCHEMBL5148324 | 0.73 | CYP3A4 (0.37) | UBE2MDCUN1D1TACR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | RXRA 2112/4885RXRG 2127/4885PTGES 1900/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | RXRA 3574/4885RXRG 3256/4885PTGES 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.